About this journal
Aims and scope
Journal of Medical Economics is a MEDLINE-indexed, international journal publishing rigorously peer-reviewed review articles and original papers in the pharmacoeconomics and healthcare research community.
Journal of Medical Economics aims to help translate research advances into patient care and lead in transparency/disclosure. The journal publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience.
Journal of Medical Economics also specializes in the publication of studies that determine the effectiveness of medical treatment, involving measurements of therapeutic and/or preventative outcomes. Methods employed in the studies commonly involve sets of patients with comparable clinical characteristics and include measurements of mortality, morbidity and patient-reported outcomes (including the patient’s quality of life, functional status and satisfaction with healthcare).
Articles focus on the following key areas:
- Economic analyses (in the form of cost minimization, cost effectiveness, cost utility, cost benefits, cost consequence, cost of illness, burden of disease)
- Health economics methodology
- Discussions on policy issues
- Resource utilization studies
- Disease management
- Modelling studies
- Meta-analyses of randomized controlled trials, outcomes and clinical trials data
All manuscripts submitted to the journal are peer-reviewed in a single-anonymized fashion. Authors can choose to publish gold open access in this journal.
*Please note that Journal of Medical Economic converted to a fully Open Access journal beginning with Volume 24 (2021). The 1998-2020 volumes will be free to access from 1 January 2021.
Journal metrics
Usage
- 928K annual downloads/views
Citation metrics
- 2.9 (2023) Impact Factor
- Q1 Impact Factor Best Quartile
- 2.9 (2023) 5 year IF
- 4.5 (2023) CiteScore (Scopus)
- Q2 CiteScore Best Quartile
- 0.942 (2023) SNIP
- 0.988 (2023) SJR
Speed/acceptance
- 23 days avg. from acceptance to online publication
- 65% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors who are deciding where to submit their next manuscript for publication. However, any one metric only tells a part of the story of a journal’s quality and impact. Each metric has its limitations which means that it should never be considered in isolation, and metrics should be used to support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside other qualitative factors such as a journal’s aims & scope, its readership, and a review of past content published in the journal. In addition, a single article should always be assessed on its own merits and never based on the metrics of the journal it was published in.
For more details, please read the Author Services guide to understanding journal metrics.
Journal metrics in brief
Usage and acceptance rate data above are for the last full calendar year and are updated annually in February. Speed data is updated every six months, based on the prior six months. Citation metrics are updated annually mid-year. Please note that some journals do not display all of the following metrics (find out why).
- Usage: the total number of times articles in the journal were viewed by users of Taylor & Francis Online in the previous calendar year, rounded to the nearest thousand.
Citation Metrics
- Impact Factor*: the average number of citations received by articles published in the journal within a two-year window. Only journals in the Clarivate Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI) have an Impact Factor.
- Impact Factor Best Quartile*: the journal’s highest subject category ranking in the Journal Citation Reports. Q1 = 25% of journals with the highest Impact Factors.
- 5 Year Impact Factor*: the average number of citations received by articles in the journal within a five-year window.
- CiteScore (Scopus)†: the average number of citations received by articles in the journal over a four-year period.
- CiteScore Best Quartile†: the journal’s highest CiteScore ranking in a Scopus subject category. Q1 = 25% of journals with the highest CiteScores.
- SNIP (Source Normalized Impact per Paper): the number of citations per paper in the journal, divided by citation potential in the field.
- SJR (Scimago Journal Rank): Average number of (weighted) citations in one year, divided by the number of articles published in the journal in the previous three years.
Speed/acceptance
- From submission to first decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision. Based on manuscripts receiving a first decision in the last six months.
- From submission to first post-review decision: the average (median) number of days for a manuscript submitted to the journal to receive a first decision if it is sent out for peer review. Based on manuscripts receiving a post-review first decision in the last six months.
- From acceptance to online publication: the average (median) number of days from acceptance of a manuscript to online publication of the Version of Record. Based on articles published in the last six months.
- Acceptance rate: articles accepted for publication by the journal in the previous calendar year as percentage of all papers receiving a final decision.
For more details on the data above, please read the Author Services guide to understanding journal metrics.
*Copyright: Journal Citation Reports®, Clarivate Analytics
†Copyright: CiteScore™, Scopus
Editorial board
Editors in Chief
Professor Kenneth KC Lee, Taylors University, Malaysia
Professor Ivo Abraham, University of Arizona, USA
Executive Editor: Mike Gregg
Editorial Board
Prof Ed Wilson, University of Exeter, UKDr Foo Chee-Yoong, IQVIA, Malaysia
Yanni Hao, Gilead Sciences, US
Nimer Alkhatib, Pi Pharma Intelligence, Jordan
Dr Ameet Bakhai, Barnet General Hospital, UK
Dr Jonathan Belsey, JB Medical, UK
Dr Christopher Blanchette, UNC Charlotte, USA
Dr Oleg Borisenko, MTRC, Sweden
Professor Nick Bosanquet, Imperial College London, UK
Dr João Carapinha, Northeastern University, Boston, MA, USA
Dr Nathorn Chaiyakunapruk, Monash University, Malaysia
Mimi Choon-Quinones, International Myeloma Foundation, Switzerland
Professor Josep Darbà, University of Barcelona, Spain
Clement Francois, Putnam, France
Dr Livio Garattini, Mario Negri Institute for Pharmacological Research, Italy
Professor Ron Goeree, McMaster University, Canada
Mr Paul E. Greenberg, Analysis Group Economics, USA
Professor Jeff Guo, University of Cincinnati, USA
Dr Michael Halpern, National Cancer Institute, USA
Dr Alan Haycox, University of Liverpool, UK
Dr. Lisa Hess, Eli Lilly, USA
Dr Mickaël Hiligsmann, Maastricht University, The Netherlands
Professor Shanlian Hu, Fudan University, China
Stuart Mealing, York Health Economics Consortium, UK
Professor Michael Hyland, University of Plymouth, UK
Professor Mihajlo Jakovljevic, University of Kragujevac, Serbia
Chia Jie Tan, University of Utah, US
Dr Vijay Joish, Bayer Healthcare Pharmaceuticals, USA
Professor Isao Kamae, Keio University, Japan
Dr Paul Kind, University of Leeds, UK
Dr Vivian Lee, Chinese University of Hong Kong, Hong Kong
Dr Won Chan Lee, Axtria - Ingenuous Insights, USA
Professor Shu Chuen Li, University of Newcastle, Australia
Professor Dr Stephen P. McKenna, Galen Research, UK
Dr Roger Lee Mendoza, California State University, USA
Dr Matthew Murawski, Purdue University, USA
Dr Chris Pashos, Takeda Pharmaceuticals, USA
Professor Paul Scuffham, Griffith University, Australia
Dominic Pilon, Analysis Group, Canada
Dr. Kitty Rajagopalan, USA
Dr Fadia T. Shaya, University of Maryland, USA
Professor Dean G. Smith, University of Michigan, USA
Professor Sean D. Sullivan, University of Washington, USA
Dr Tomomi Takeshima, Milliman, Japan
Mr Adrian Towse, Office for Health Economics, UK
Professor David Wu, National University of Singapore, Singapore
Dr Bong-Min Yang, Seoul National University, Republic of Korea
Dr York Francis Zöllner, Hamburg University of Applied Sciences, Germany
Early Career Panel 2023/4
Mavis Obeng-Kusi, Merck & Co., US
Neda Rawashdh, IQVIA, US
Abdulaali R. Almutairi, Saudi Food and Drug Authority, Saudi Arabia
Abstracting and indexing
Journal ofMedical Economics is included in the following abstracting and indexing services:
- MEDLINE
- PubMed
- EMBASE
- Scopus
- Science Citation Index Expanded
- International Pharmaceutical Abstracts
- CAB Health/CAB Abstracts
- Pharm-line
- Cochrane Registry
- Health Service Abstracts
- NHS EED
- HEED.
Open access
Journal of Medical Economics is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
- Increase the discoverability and readership of your article
- Make an impact and reach new readers, not just those with easy access to a research library
- Freely share your work with anyone, anywhere
- Comply with funding mandates and meet the requirements of your institution, employer or funder
- Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Use our APC finder to calculate your article publishing charge
Continuous publication
Advertising information
Would you like to advertise in Journal of Medical Economics?
Reach an engaged target audience and position your brand alongside authoritative peer-reviewed research by advertising in Journal of Medical Economics.
Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
Go to submission site (link opens in a new window) Instructions for authors